AstraZeneca has launched a new global health tech business, Evinova, with the goal of revolutionizing the clinical trial process. The company aims to reduce the time and cost of clinical trials and make the process easier for patients. Evinova operates as a separate business financially backed by AstraZeneca and provides global services to CROs and pharmaceutical companies to design, run, and monitor clinical trials.
Evinova’s technology will be accessible to customers at a cost, and the company operates on a revenue-based model. By creating this new venture, AstraZeneca hopes to address the challenges and inefficiencies in the clinical trial process, ultimately making it easier for patients to participate and improving overall trial effectiveness. This move reflects AstraZeneca’s commitment to advancing healthcare through technology-driven innovation in drug development.